Volume | 952,922 |
|
|||||
News | - | ||||||
Day High | 21.33 | Low High |
|||||
Day Low | 20.565 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Revolution Medicines Inc | RVMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
20.91 | 20.565 | 21.33 | 21.03 | 20.92 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
15,473 | 952,922 | $ 20.98 | $ 19,995,071 | - | 14.08 - 31.37 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:01:36 | formt | 434 | $ 21.03 | USD |
Revolution Medicines Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 2.23B | 106.17M | 94.45M | $ 35.38M | $ - | -3.08 | -7.60 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | -3.81k | 1.00% |
Revolution Medicines News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVMD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 21.45 | 22.41 | 20.27 | 21.16 | 1,020,641 | -0.42 | -1.96% |
1 Month | 24.44 | 28.14 | 19.70 | 24.07 | 2,306,299 | -3.41 | -13.95% |
3 Months | 23.73 | 31.37 | 19.70 | 24.94 | 1,426,243 | -2.70 | -11.38% |
6 Months | 18.80 | 31.37 | 17.47 | 23.51 | 1,153,112 | 2.23 | 11.86% |
1 Year | 24.14 | 31.37 | 14.08 | 22.45 | 1,007,436 | -3.11 | -12.88% |
3 Years | 24.00 | 56.18 | 14.08 | 27.36 | 659,770 | -2.97 | -12.38% |
5 Years | 29.35 | 56.18 | 14.08 | 27.39 | 655,194 | -8.32 | -28.35% |
Revolution Medicines Description
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |